Table 1.
Patient characteristics of each cohort
| Characteristic | RNA-seq derivation cohort |
RNA-seq validation cohort |
IFN proteins profile cohort |
|||
|---|---|---|---|---|---|---|
| Controls (N = 5) | Patients with COVID-19 (N = 10) | Controls (N = 16) | Patients with COVID-19 (N = 31) | Controls (N = 19) | Patients with COVID-19 (N = 203) | |
| Age, median, IQR | 71 (67–79.5) | 74 (66–78.8) | 55 (34–59.5) | 73 (62–76) | 58 (55–71) | 67 (57–74) |
| Sex, male (%) | 3 (60) | 5 (50) | 8 (50) | 22 (70.1) | 13 (68.4) | 144 (70.9) |
| BMI, median IQR | 21.5 (19.7–26.3) | 24.9 (22.3–26.5) | 22 (20.3–24.6) | 22.7 (21.8–25.2) | 21.7 (20.1–24.8) | 25.0 (22.8–27.8) |
| Comorbidities, n (%) | ||||||
| Diabetes | 0 (0) | 7 (70) | 1 (6.2) | 12 (38.7) | 1 (5.3) | 78 (38.4) |
| Hypertension | 2 (40) | 3 (30) | 2 (12.5) | 16 (51.6) | 4 (21.1) | 99 (48.8) |
| Hyperlipidemia | 3 (60) | 2 (20) | 6 (37.5) | 10 (32.3) | 10 (52.6) | 62 (30.5) |
| Hyperuricemia | 0 (0) | 0 (0) | 1 (6.3) | 6 (19.4) | 1 (5.3) | 23 (11.3) |
| Chronic heart disease | 1 (20) | 1 (10) | 1 (6.3) | 2 (6.5) | 2 (10.5) | 22 (10.8) |
| Chronic lung disease | 0 (0) | 1 (10) | 0 (0) | 6 (19.4) | 0 (0) | 26 (12.8) |
| Chronic kidney disease | 0 (0) | 1 (10) | 0 (0) | 7 (22.6) | 0 (0) | 23 (11.3) |
| Immunocompromised condition | 0 (0) | 0 (0) | 0 (0) | 5 (16.1) | 0 (0) | 6 (3.0) |
| Malignant neoplasm | 0 (0) | 3 (30) | 0 (0) | 0 (0) | 0 (0) | 16 (7.9) |
| Length of hospitalization | 24.5 (6.5–71.8) | 21 (13–41) | 11 (7–17.8) | |||
| Acuity score | ||||||
| 1 = death | 1 (10) | 4 (12.9) | 31 (15.3) | |||
| 2 = intubated/ventilated, survived | 9 (90) | 27 (87.1) | 160 (78.8) | |||
| 3 = hospitalized, O2 required, survived | 0 (0) | 0 (0) | 12 (5.9) | |||
| 4 = hospitalized, no O2 required, survived | 0 (0) | 0 (0) | 0 (0) | |||
| 5 = discharged/not hospitalized, survived | 0 (0) | 0 (0) | 0 (0) | |||
| Intubation required, n (%) | 10 (100) | 31 (100) | 185 (91.1) | |||
| Extracorporeal membrane oxygenation | 2 (20) | 3 (9.7) | 9 (4.8) | |||
| Late recovery, n (%) | 5 (50) | 19 (61.3) | 89 (43.8) | |||
| SOFA score, median, IQR | 5.5 (2.5–6) | 6 (3–6) | 5 (3–6) | |||
| APACHE II score, median, IQR | 16 (15.25–18.8) | 12 (10–17) | 12 (9–15) | |||
| Clade, n (%) | ||||||
| 20A | 0 (0) | 0 (0) | 1 (0.5) | |||
| 20B | 3 (30) | 20 (64.5) | 22 (10.8) | |||
| 20I (Alpha, V1) | 0 (0) | 0 (0) | 14 (6.9) | |||
| Unknown | 7 (70) | 11 (35.5) | 166 (81.8) | |||
IQR, interquartile range; BMI, body mass index; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation.
Data are shown as group number (percentage) or median (IQR).